scispace - formally typeset
L

Lucia Altucci

Researcher at Seconda Università degli Studi di Napoli

Publications -  363
Citations -  21673

Lucia Altucci is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Epigenetics & Medicine. The author has an hindex of 60, co-authored 308 publications receiving 16687 citations. Previous affiliations of Lucia Altucci include University of Salerno & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Lorenzo Galluzzi, +186 more
TL;DR: The Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives.
Journal Article

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

Lorenzo Galluzzi, +168 more
- 01 Jan 2018 - 
TL;DR: An updated classification of cell death subroutines focusing on mechanistic and essential aspects of the process is proposed, and the utility of neologisms that refer to highly specialized instances of these processes are discussed.
Journal ArticleDOI

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015

Lorenzo Galluzzi, +121 more
TL;DR: The Nomenclature Committee on Cell Death formulates a set of recommendations to help scientists and researchers to discriminate between essential and accessory aspects of cell death.
Journal ArticleDOI

The promise of retinoids to fight against cancer

TL;DR: Understanding of the mechanisms that underlie the anti-proliferative action of retinoids will help to exploit the beneficial aspects of this powerful class of compounds for cancer therapy and prevention.
Journal ArticleDOI

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.

TL;DR: It is reported that HDACIs induce, in addition to p21, expression of TRAIL by directly activating the TNFSF10 promoter, thereby triggering tumor-selective death signaling in acute myeloid leukemia (AML) cells and the blasts of individuals with AML.